EA201170353A1 - Антитела против гепатита с и их применение - Google Patents

Антитела против гепатита с и их применение

Info

Publication number
EA201170353A1
EA201170353A1 EA201170353A EA201170353A EA201170353A1 EA 201170353 A1 EA201170353 A1 EA 201170353A1 EA 201170353 A EA201170353 A EA 201170353A EA 201170353 A EA201170353 A EA 201170353A EA 201170353 A1 EA201170353 A1 EA 201170353A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hcv
present
provides
antibodies
conformational epitopes
Prior art date
Application number
EA201170353A
Other languages
English (en)
Russian (ru)
Inventor
Стивен Фоунг
Кек Чжэнь-Юн
Original Assignee
Зэ Борд Оф Трастис Оф Зэ Лилэнд Стэнфорд Джуниор Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Зэ Борд Оф Трастис Оф Зэ Лилэнд Стэнфорд Джуниор Юниверсити filed Critical Зэ Борд Оф Трастис Оф Зэ Лилэнд Стэнфорд Джуниор Юниверсити
Publication of EA201170353A1 publication Critical patent/EA201170353A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • C07K16/118—Hepatitis C virus; GB virus C [GBV-C]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EA201170353A 2008-10-05 2008-10-05 Антитела против гепатита с и их применение EA201170353A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/078884 WO2010039154A1 (en) 2008-10-05 2008-10-05 Hepatitis c antibodies and uses thereof

Publications (1)

Publication Number Publication Date
EA201170353A1 true EA201170353A1 (ru) 2011-12-30

Family

ID=42073762

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201170353A EA201170353A1 (ru) 2008-10-05 2008-10-05 Антитела против гепатита с и их применение

Country Status (12)

Country Link
US (1) US8858947B2 (https=)
EP (1) EP2331573A4 (https=)
JP (1) JP2012504602A (https=)
KR (1) KR20110061624A (https=)
CN (1) CN102197050A (https=)
AU (1) AU2008362482A1 (https=)
BR (1) BRPI0823197A2 (https=)
CA (1) CA2738644A1 (https=)
EA (1) EA201170353A1 (https=)
IL (1) IL212040A0 (https=)
MX (1) MX2011003613A (https=)
WO (1) WO2010039154A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2495256A4 (en) * 2009-10-30 2013-09-25 Toray Industries ANTIBODIES WITH HEMMETAL EFFECT ON INFECTIONS WITH HEPATITIS C VIRUS (HCV) AND ITS USE
WO2012107589A1 (en) * 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
EP2705150B1 (en) * 2011-05-02 2020-07-29 The Johns Hopkins University A synthetic hepatitis c genome and methods of making and use
MX366886B (es) 2012-08-07 2019-07-30 Massachusetts Inst Technology Anticuerpos anti-virus del dengue y usos de los mismos.
CN103113458B (zh) * 2013-02-27 2014-08-20 北京大学人民医院 丙型肝炎病毒b细胞表位肽puhi34及其应用
CN103172705B (zh) * 2013-02-27 2014-08-20 北京大学人民医院 丙型肝炎病毒b细胞表位肽puhi16及其应用
RU2539770C1 (ru) * 2013-12-27 2015-01-27 Татьяна Николаевна Власик Способ нейтрализации вируса гепатита с, полностью человеческое моноклональное антитело против вируса гепатита с (варианты), композиция полностью человеческих моноклональных антител против вируса гепатита с и гибридная мышь/человек клеточная линия - продуцент полностью человеческих моноклональных антител против вируса гепатита с (варианты)
KR20160119806A (ko) 2014-02-11 2016-10-14 메사추세츠 인스티튜트 오브 테크놀로지 신규한 온전한 범위의 항-뎅기 항체
WO2015133467A1 (ja) * 2014-03-06 2015-09-11 株式会社シノテスト Ｃ型肝炎ウイルスのワクチン及び診断に用いるためのＨＢｃ／ＨＣＶ Ｅ２ペプチドキメラタンパク質
CN104327170A (zh) * 2014-05-16 2015-02-04 中国疾病预防控制中心病毒病预防控制所 丙型肝炎病毒(hcv)细胞进入抑制肽zte1序列及应用
GB201415714D0 (en) * 2014-09-05 2014-10-22 Medical Res Council Antibodies and antigen binding fragments thereof
CN105254756B (zh) * 2015-11-27 2018-09-07 武汉大学 一种针对丙型肝炎病毒包膜蛋白e2的单克隆抗体及应用
CN109641955B (zh) * 2016-03-22 2022-07-08 国家医疗保健研究所 人源化抗claudin-1抗体及其用途
CN107011435B (zh) * 2016-06-01 2019-02-12 苏州银河生物医药有限公司 抗丙型肝炎病毒的全人单克隆抗体8d6
EP4095156A1 (en) * 2021-05-28 2022-11-30 Universität zu Köln Neutralizing antibodies against hepatitis c virus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1462300A (en) * 1998-11-05 2000-05-22 Board Of Trustees Of The Leland Stanford Junior University Human pan-hcv human monoclonal antibodies
US7091324B2 (en) * 1998-11-05 2006-08-15 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
ES2529736T3 (es) * 2003-04-10 2015-02-25 Novartis Vaccines And Diagnostics, Inc. Composición inmunogénica que comprende una proteína espicular del coronavirus del SARS

Also Published As

Publication number Publication date
AU2008362482A1 (en) 2010-04-08
IL212040A0 (en) 2011-06-30
WO2010039154A1 (en) 2010-04-08
JP2012504602A (ja) 2012-02-23
KR20110061624A (ko) 2011-06-09
EP2331573A4 (en) 2012-09-05
US8858947B2 (en) 2014-10-14
MX2011003613A (es) 2011-08-03
BRPI0823197A2 (pt) 2015-06-23
CN102197050A (zh) 2011-09-21
US20120039846A1 (en) 2012-02-16
EP2331573A1 (en) 2011-06-15
CA2738644A1 (en) 2010-05-08

Similar Documents

Publication Publication Date Title
EA201170353A1 (ru) Антитела против гепатита с и их применение
WO2006041866A3 (en) Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes
EA201071087A1 (ru) Моноклональные антитела, способные взаимодействовать с множеством подтипов вируса гриппа а
EA201071365A1 (ru) Моноклональные антитела, имеющие гомоподтип кросс-нейтрализующих свойств против вируса гриппа а подтипа н1
EA201390874A1 (ru) Моноклональное антитело человека со специфичностью к белку e вируса денге серотипа 1 и его применение
EA200900298A1 (ru) Ингибиторы вируса гепатита с
EA201201116A1 (ru) Моноклональные антитела человека, полученные из в-клеток человека и обладающие нейтрализующей активностью против вирусов гриппа а
EA200970586A1 (ru) Антитела к цитомегаловирусу человека (hcmv)
CY1114356T1 (el) Αναστολεις του ιου της ηπατιτιδας c
UA109633C2 (uk) Антитіло людини проти тканинного фактора
EA201391170A1 (ru) Терапевтическое средство на основе дрожжей для лечения хронического гепатита b
EA201171208A1 (ru) Ингибиторы вируса гепатита с
EA201270656A1 (ru) Ингибиторы вируса гепатита с
EA200900297A1 (ru) Ингибиторы вируса гепатита с
DE602005027258D1 (de) Humane monoklonale antikörper gegen hendra- und nipah-viren
JP2010521147A5 (https=)
BR112014004860A2 (pt) composições de anticorpo contra vírus da influenza
ATE473760T1 (de) Monoklonale antikörper gegen den hepatozyten- wachstumsfaktor
EA201390806A1 (ru) Конструкция пептидного каркаса
EA201391685A1 (ru) Ингибиторы вируса гепатита с
WO2009152147A3 (en) Compositions and methods for dengue virus (dv) treatment and vaccination
EA201000277A1 (ru) Соединения для лечения гепатита с
WO2012006500A3 (en) Monoclonal antibodies against hepatitis c virus core protein
EA201300132A1 (ru) Фармацевтическая композиция и методы лечения и профилактики заболеваний, вызванных вич или ассоциированных с вич
EA201170484A1 (ru) Терапевтический режим лечения гепатита, включающий пэг-интерферон, рибавирин и vx-950